Effect of statin therapy on mortality from infection and sepsis: A meta-analysis of randomized and observational studies

Critical Care

Volumn 18, Issue 2, 2014, Pages

  Wan, You Dong ^a   Sun, Tong Wen ^a   Kan, Quan Cheng ^a   Guan, Fang Xia ^b   Zhang, Shu Guang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b Academy of Medical Science   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; BACTEREMIA; HUMAN; INFECTION; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEPSIS; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TRENDS;

HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFECTION; OBSERVATIONAL STUDY AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; TREATMENT OUTCOME;

EID: 84899937720     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13828     Document Type: Article

References (55)

1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G. SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003, 2001:1250-1256.
2. Lever A, Mackenzie I. Sepsis: definition, epidemiology, and diagnosis. BMJ 2007, 335:879-883. 10.1136/bmj.39346.495880.AE, 2043413, 17962288.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002, 11445675.
4. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554. 10.1056/NEJMoa022139, 12700374.
5. Perl TM, Dvorak L, Hwang T, Wenzel RP. Long-term survival and function after suspected gram-negative sepsis. JAMA 1995, 274:338-345. 10.1001/jama.1995.03530040066043, 7609265.
6. Almog Y. Statins, inflammation, and sepsis: hypothesis. Chest 2003, 124:740-743. 10.1378/chest.124.2.740, 12907568.
7. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2008, 61:362-364.
8. Arnaud C, Mach F. Potential antiinflammatory and immunomodulatory effects of statins in rheumatologic therapy. Arthritis Rheum 2006, 54:390-392. 10.1002/art.21757, 16447215.
9. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim T. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 2009, 169:1658-1667. 10.1001/archinternmed.2009.286, 19822822.
10. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 2010, 25:656-657.
11. van den Hoek HL, Bos WJ, de Boer A, van de Garde EM. Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials. BMJ 2011, 343:d7281. 10.1136/bmj.d7281, 3226140, 22127443.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269. W64, 10.7326/0003-4819-151-4-200908180-00135, 19622511.
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12. 10.1016/0197-2456(95)00134-4, 8721797.
14. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001, 135:982-989. 10.7326/0003-4819-135-11-200112040-00010, 11730399.
15. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead?. BMJ 1998, 316:989-991. 10.1136/bmj.316.7136.989, 1112884, 9550961.
16. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634. 10.1136/bmj.315.7109.629, 2127453, 9310563.
17. Novack V, Eisinger M, Frenkel A, Terblanche M, Adhikari NK, Douvdevani A, Amichay D, Almog Y. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive Care Med 2009, 35:1255-1260. 10.1007/s00134-009-1429-0, 19205663.
18. Kruger PS, Harward ML, Jones MA, Joyce CJ, Kostner KM, Roberts MS, Venkatesh B. Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med 2011, 183:774-781. 10.1164/rccm.201006-0955OC, 20959555.
19. Patel JM, Snaith C, Thickett DR, Linhartova L, Melody T, Hawkey P, Barnett AH, Jones A, Hong T, Cooke MW, Perkins GD, Gao F. Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Crit Care 2012, 16:R231. 10.1186/cc11895, 3672620, 23232151.
20. Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, Higgins A, Howe B, Jones D, Joyce C, Kostner K, McNeil J, Nichol A, Roberts MS, Syres G, Venkatesh B. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med 2013, 187:743-750. 10.1164/rccm.201209-1718OC, 23348980.
21. Papazian L, Roch A, Charles PE, Penot-Ragon C, Perrin G, Roulier P, Goutorbe P, Lefrant JY, Wiramus S, Jung B, Perbet S, Hernu R, Nau A, Baldesi O, Allardet-Servent J, Baumstarck K, Jouve E, Moussa M, Hraiech S, Guervilly C, Forel JM. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA 2013, 310:1692-1700. 10.1001/jama.2013.280031, 24108510.
22. Rothberg MB, Bigelow C, Pekow PS, Lindenauer PK. Association between statins given in hospital and mortality in pneumonia patients. J Gen Intern Med 2012, 27:280-286. 10.1007/s11606-011-1826-2, 3286569, 21842322.
23. Yende S, Milbrandt EB, Kellum JA, Kong L, Delude RL, Weissfeld LA, Angus DC. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med 2011, 39:1871-1878. 10.1097/CCM.0b013e31821b8290, 3139804, 21516038.
24. Forrest GN, Kopack AM, Perencevich EN. Statins in candidemia: clinical outcomes from a matched cohort study. BMC Infect Dis 2010, 10:152. 10.1186/1471-2334-10-152, 2894022, 20525374.
25. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sorensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. Arch Intern Med 2008, 168:2081-2087. 10.1001/archinte.168.19.2081, 18955636.
26. Donnino MW, Cocchi MN, Howell M, Clardy P, Talmor D, Cataldo L, Chase M, Al-Marshad A, Ngo L, Shapiro NI. Statin therapy is associated with decreased mortality in patients with infection. Acad Emerg Med 2009, 16:230-234. 10.1111/j.1553-2712.2009.00350.x, 19281494.
27. Doshi SM, Kulkarni PA, Liao JM, Rueda AM, Musher DM. The impact of statin and macrolide use on early survival in patients with pneumococcal pneumonia. Am J Med Sci 2013, 345:173-177. 10.1097/MAJ.0b013e3182639c26, 23111390.
28. Yeh PS, Lin HJ, Chen PS, Lin SH, Wang WM, Yang CM, Li YH. Effect of statin treatment on three-month outcomes in patients with stroke-associated infection: a prospective cohort study. Eur J Neurol 2012, 19:689-695. 10.1111/j.1468-1331.2011.03608.x, 22176026.
29. Goodin J, Manrique C, Dulohery M, Sampson J, Saettele M, Dabbagh O. Effect of statins on the clinical outcomes of patients with sepsis. Anaesth Intensive Care 2011, 39:1051-1055.
30. Nseir W, Mograbi J, Abu-Elheja O, Bishara J, Assy N. The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients. Infection 2012, 40:41-48. 10.1007/s15010-011-0190-9, 21894571.
31. Williams JM, Greenslade JH, Chu K, Brown AF, Paterson D, Lipman J. Prior statin use is not associated with improved outcome in emergency patients admitted with infection: a prospective observational study. Acad Emerg Med 2011, 18:127-134. 10.1111/j.1553-2712.2010.00976.x, 21314770.
32. Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJ, McKeever TM. The impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohort. Pharmacoepidemiol Drug Saf 2009, 18:697-703. 10.1002/pds.1769, 19455553.
33. Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008, 121:1002-1007. 10.1016/j.amjmed.2008.06.030, 18954848.
34. Mortensen EM, Nakashima B, Cornell J, Copeland LA, Pugh MJ, Anzueto A, Good C, Restrepo MI, Downs JR, Frei CR, Fine MJ. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis 2012, 55:1466-1473. 10.1093/cid/cis733, 3491858, 22918991.
35. Leung S, Pokharel R, Gong MN. Statins and outcomes in patients with bloodstream infection: a propensity-matched analysis. Crit Care Med 2012, 40:1064-1071. 10.1097/CCM.0b013e31823bc9e7, 3566662, 22202711.
36. Yang KC, Chien JY, Tseng WK, Hsueh PR, Yu CJ, Wu CC. Statins do not improve short-term survival in an oriental population with sepsis. Am J Emerg Med 2007, 25:494-501. 10.1016/j.ajem.2006.09.011, 17543651.
37. Kruger P, Fitzsimmons K, Cook D, Jones M, Nimmo G. Statin therapy is associated with fewer deaths in patients with bacteraemia. Intensive Care Med 2006, 32:75-79. 10.1007/s00134-005-2859-y, 16283159.
38. Hsu J, Andes DR, Knasinski V, Pirsch J, Safdar N. Statins are associated with improved outcomes of bloodstream infection in solid-organ transplant recipients. Eur J Clin Microbiol Infect Dis 2009, 28:1343-1351. 10.1007/s10096-009-0787-4, 19669657.
39. Mortensen EM, Pugh MJ, Copeland LA, Restrepo MI, Cornell JE, Anzueto A, Pugh JA. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008, 31:611-617. 10.1183/09031936.00162006, 17959631.
40. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007, 131:1006-1012. 10.1378/chest.06-1997, 17426203.
41. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001, 33:1352-1357. 10.1086/323334, 11565076.
42. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res 2005, 6:82. 10.1186/1465-9921-6-82, 1199623, 16042797.
43. Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, Sorensen HT, Schonheyder HC, Lervang HH. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med 2006, 34:1080-1086. 10.1097/01.CCM.0000207345.92928.E4, 16484926.
44. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ 2006, 333:999. 10.1136/bmj.38992.565972.7C, 1635620, 17060337.
45. Dobesh PP, Klepser DG, McGuire TR, Morgan CW, Olsen KM. Reduction in mortality associated with statin therapy in patients with severe sepsis. Pharmacotherapy 2009, 29:621-630. 10.1592/phco.29.6.621, 19476415.
46. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004, 110:880-885. 10.1161/01.CIR.0000138932.17956.F1, 15289367.
47. Mortensen EM, Restrepo MI, Copeland LA, Pugh JA, Anzueto A, Cornell JE, Pugh MJ. Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis. Pharmacotherapy 2007, 27:1619-1626. 10.1592/phco.27.12.1619, 18041882.
48. Park SW, Choi AR, Lee HJ, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Kim JE, Lee H. The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients. Aliment Pharmacol Ther 2013, 38:619-627. 10.1111/apt.12439, 23888883.
49. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AJ, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207. 10.1056/NEJMoa0807646, 18997196.
50. Makris D, Manoulakas E, Komnos A, Papakrivou E, Tzovaras N, Hovas A, Zintzaras E, Zakynthinos E. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. Crit Care Med 2011, 39:2440-2446. 10.1097/CCM.0b013e318225742c, 21725239.
51. Thomsen RW, Johnsen SP, Olesen AV, Mortensen JT, Boggild H, Olsen J, Sorensen HT. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005, 60:534-542. 10.1111/j.1365-2125.2005.02494.x, 1884943, 16236044.
52. Fang JC. Heart failure therapy: what should clinicians believe?. JAMA 2012, 308:2144-2146. 10.1001/jama.2012.45418, 23188032.
53. Tseng MY, Hutchinson PJ, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ. Effects of acute pravastatin treatment on intensity of rescue therapy, length of inpatient stay, and 6-month outcome in patients after aneurysmal subarachnoid hemorrhage. Stroke 2007, 38:1545-1550. 10.1161/STROKEAHA.106.475905, 17413047.
54. Pasin L, Landoni G, Castro ML, Cabrini L, Belletti A, Feltracco P, Finco G, Carozzo A, Chiesa R, Zangrillo A. The effect of statins on mortality in septic patients: a meta-analysis of randomized controlled trials. PLoS One 2013, 8:e82775. 10.1371/journal.pone.0082775, 3876996, 24391721.
55. Shyamsundar M, McKeown ST, O'Kane CM, Craig TR, Brown V, Thickett DR, Matthay MA, Taggart CC, Backman JT, Elborn JS, McAuley DF. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009, 179:1107-1114. 10.1164/rccm.200810-1584OC, 2695496, 19324974.